Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Krystal Biotech ( (KRYS) ) just unveiled an announcement.
On July 9, 2025, Krystal Biotech announced the dosing of the first patient in its Phase 1/2 trial of KB801, a gene therapy eye drop for neurotrophic keratitis (NK), a degenerative corneal disease. The trial, named EMERALD-1, aims to evaluate the safety and efficacy of KB801, which promises to reduce treatment burden by enabling sustained expression of nerve growth factor in the eye. The company also hosted a conference call and webcast to discuss the trial and its implications, highlighting the potential of KB801 to address the unmet needs of NK patients.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Krystal Biotech’s strong financial performance, positive earnings call, and impactful corporate events significantly enhance its stock rating. While technical indicators and valuation present some reservations, the overall outlook remains optimistic due to robust growth prospects and strategic initiatives.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. is a global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company is advancing a pipeline of investigational genetic medicines across various fields, including respiratory, oncology, dermatology, ophthalmology, and aesthetics. It is headquartered in Pittsburgh, Pennsylvania.
Average Trading Volume: 362,332
Technical Sentiment Signal: Sell
Current Market Cap: $4.04B
For an in-depth examination of KRYS stock, go to TipRanks’ Overview page.